← Evidence map

ArticleClinical pharmacokinetics2020

Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"

D Concordet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?" | OpenQuestion